Search

everythinglearnresearchcommunity

for

Search:↓

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

Targeting the Smoothened receptor shows promise for treating certain cancers.

MK-5108 is safe and shows potential against tumors, especially alone.

Delta-opioid receptors affect skin cell circadian rhythms, possibly impacting wound healing and cancer.

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

Baricitinib effectively reduces hair loss in severe alopecia areata with mild side effects.

Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Baricitinib is a promising treatment for alopecia areata.

Arteannuin might work against cancer and Alzheimer's by targeting neprilysin.

Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.

The article concludes that hair loss is a common side effect of drugs treating skin cancer by blocking the hedgehog pathway, but treatment should continue, and more selective drugs might prevent this side effect.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.

Removing MCPIP1 from myeloid cells in mice leads to hair loss and prevents skin tumors but causes pigmented spots.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

Erlotinib can cause acne-like skin issues, needing early treatment and possible dosage adjustments.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Rapamycin treatment helps with mitochondrial disease by reducing PKC levels.

Transcranial electrical stimulation with bisphosphonates helps maintain bone collagen better than bisphosphonates alone.

Low-dose rapamycin microdepots can help regrow hair by activating certain cell processes.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

PRP injection for hair growth can cause reversible vision loss due to inflammatory optic neuropathy.

Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.